Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors

Medical and Pediatric Oncology

Volumn 33, Issue 5, 1999, Pages 450-454

  Pession, Andrea ^a,e   Prete, Arcangelo ^a   Locatelli, Franco ^b   Bella, Santiago ^c   Melchionda, Fraia ^a   Garaventa, Alberto ^d   Burnelli, Roberta ^a   Paolucci, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autologous stem cell transplantation; Solid tumors; Thiotepa

Indexed keywords

BUSULFAN; ETOPOSIDE; THIOTEPA;

ADOLESCENT; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEUROBLASTOMA; PROGNOSIS; RHABDOMYOSARCOMA; SARCOMA, EWING'S; THIOTEPA;

EID: 0032758106     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199911)33:5<450::AID-MPO3>3.0.CO;2-L     Document Type: Article

References (19)

1. Frei E III, Antman K, Teicher B, et al. Bone marrow autotransplantation for solid tumors prospects. J Clin Oncol 1989;7:515-526.
2. Frei E III, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 1980;68:585-594.
3. Wolff S, Herzig R, Fay J, et al. High-dose N,N′,N″-triethylene-thiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase i studies. Semin Oncol 1990;17:2-6.
4. Heideman RL, Packer RJ, Reaman GH, et al. A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 1993;72:271-275.
5. Dupuis G, Hartmann O, Benhamou E, et al. High dose chemotherapy in relapsed medulloblastoma in young children. Bull Cancer 1997;84:264-272.
6. Finlay JL, Goldman S, Wong ML, et al. Pilot study of high dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. J Clin Oncol 1996;14:2495-2503.
7. Schabel FM Jr, Griswold DP Jr, Corbett TH, et al. Increasing the therapeutic response rates to antitumor drugs by applying the basic principles of pharmacology. Pharmacol Ther 1983;20:283-305.
8. Nowak C, Steinhoff G, Arnold W. Testing ifos/mesna and VP 16 combination therapy in the P 388 leukemia model. Contrib Oncol 1987;26:2465-2469.
9. Balmaceda C, Fetell MR, Hesdorffer C. Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study. Cancer Chemother Pharmacol 1997;40:72-74.
10. Geyer JR, Balis FM, Krailo MD, et al. A phase II study of thio-TEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. Invest New Drugs 1996;13:337-342.
11. Hussein AM, Petros WP, Ross M, et al. A phase I/II study of high dose cyclophosphamide, cisplatin and thiotepa followed by autologous bone marrow and granulocyte colony stimulating factor primed peripheral blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol 1996;37:561-568.
12. Regazzi MB, Locatelli F, Buggia I, et al. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clin Pharmacol Ther 1993;54:45-51.
13. Buggia I, Locatelli F, Regazzi M, et al. Busulfan. Ann Pharmacother 1994;28:1055-1062.
14. Bondi E, Baroni C, Prete A, et al: Local antimicrobial therapy of oral mucositis in paediatric patients undergoing bone marrow transplantation. Oral Oncol 1997;33:322-326.
15. Ungerleider RS, Marsoni S. Phase I and II trials in pediatric cancer patients: a rationale. In: Poplack DG, Massimo C, Cornaglia P, editors. The role of pharmacology in pediatric oncology. Boston: Martinus Nighoft Publishers; 1987. p 159-171.
16. Woolley PV, Schein PS. Clinical pharmacology and Phase I trial design. In: De Vita V, Bush M. editors. Methods in cancer research, Vol 7: cancer drug developement, part B. San Diego: Academic Press; 1979. p 177-198.
17. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
18. Kamani N, August CS, Bunin N, et al. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 1996;17: 911-916.
19. Grill J, Kalifa C, Doz F, et al. A high-dose busulfan thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase II study. Pediatr Neurosurg 1996;25:7-12.